In the 14 studies analysed, CDKN2A was significantly higher in patients with pancreatic cancer then in healthy controls (OR 17.2, p < 0.00001), however the low sensitivity (41%) and positive predictive value (58%) make it an unsuitable diagnostic biomarker (Tang et al. 2015). Here, CDKN2A is linked to pancreatic neoplasm.